The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global uveitis treatment market reached a value of US$ 550 Million in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of eye and sensitivity to light. Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines. These therapeutics are directed toward reducing inflammation, alleviating pain, preventing further tissue damage and restoring vision loss and can be used to treat conditions, including anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.
The increasing prevalence of optical infections and chronic eye disorders across the globe represents one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy and autoimmune and inflammatory disorders. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness regarding the available treatment alternatives for managing uveitis has resulted in a significant increase in the demand for corticosteroid treatments among patients and healthcare providers. Additionally, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors. These biological therapeutic agents are effective in the treatment of chronic uveitis and are administered as subcutaneous injections. Other factors, including the implementation of favorable initiatives by the governments to promote public health, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global uveitis treatment market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, Treatment Type, Disease Type, Cause and Distribution Channel.
Breakup by Treatment Type:
Breakup by Disease Type:
Breakup by Cause:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Treatment Type, Disease Type, Cause, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at